ASKA Pharmaceutical Holdings Co., Ltd. Sustainability Profile
ASKA Pharmaceutical Holdings Co., Ltd., commonly referred to as ASKA Pharma, is a prominent player in the pharmaceutical industry, headquartered in Japan. Founded in 1941, the company has established a strong presence in various operational regions, including Asia and beyond. ASKA Pharma focuses on the development, manufacturing, and marketing of innovative pharmaceuticals, particularly in the fields of neurology, urology, and oncology. With a commitment to research and development, ASKA Pharma has achieved significant milestones, including the introduction of unique therapeutic solutions that address unmet medical needs. The company is recognised for its high-quality products, which are distinguished by their efficacy and safety profiles. ASKA Pharma's dedication to advancing healthcare has solidified its position as a trusted name in the pharmaceutical sector, contributing to improved patient outcomes globally.
DitchCarbon Score
How does ASKA Pharmaceutical Holdings Co., Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
ASKA Pharmaceutical Holdings Co., Ltd.'s score of 31 is higher than 53% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
ASKA Pharmaceutical Holdings Co., Ltd.'s reported carbon emissions
In 2023, ASKA Pharmaceutical Holdings Co., Ltd. reported total carbon emissions of approximately 6,055,000 kg CO2e for Scope 1 and about 2,949,000 kg CO2e for Scope 2. This marks a reduction from 2022, where emissions were approximately 6,687,000 kg CO2e for Scope 1 and about 4,093,000 kg CO2e for Scope 2. The company has not disclosed any Scope 3 emissions data. Despite these reductions, ASKA Pharmaceutical has not set specific reduction targets or climate pledges, nor does it participate in initiatives such as the Science Based Targets initiative (SBTi). The absence of formal commitments indicates a potential area for growth in their climate strategy. Overall, ASKA Pharmaceutical's emissions data reflects a commitment to monitoring and reducing their carbon footprint, although further initiatives and targets could enhance their climate impact.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 6,687,000 | 0,000,000 |
| Scope 2 | 4,093,000 | 0,000,000 |
| Scope 3 | - | - |
How Carbon Intensive is ASKA Pharmaceutical Holdings Co., Ltd.'s Industry?
How Carbon Intensive is ASKA Pharmaceutical Holdings Co., Ltd.'s Location?
ASKA Pharmaceutical Holdings Co., Ltd.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
ASKA Pharmaceutical Holdings Co., Ltd. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
